In the future, antifibrotic treatment by targeting the CYP19/estrogen/GPER signaling pathway combined with current drugs may be effective in delaying the progression of BPH patients with prostatic fibrosis [6, 8, 61]. The gene discussed is CYP19A1; the disease is benign prostatic hyperplasia.